Philips receives FDA 510(k) clearance for Verida, the world’s first AI-powered detector-based spectral CT*, advancing diagnostic precision across clinical applications

Rhea-AI Summary

Royal Philips (NYSE: PHG) received FDA 510(k) clearance on April 16, 2026 for the Philips Spectral CT Verida, the company’s AI-powered, detector-based spectral CT system. Verida combines always-on dual-layer detection with an AI deep-learning reconstruction (Spectral Precise Image), reconstructing 145 images/sec and producing full exams in under 30 seconds, enabling up to 270 exams per day. Indications include radiology, interventional radiology, cardiology, oncology, and low-dose lung cancer screening within established protocols. Certain features have use limitations (pediatric validation and treatment-planning-specific modes); Spectral Precise Image is supplemental to clinical judgment.

Positive

• FDA 510(k) clearance for Verida expands US market access
• Reconstructs 145 images per second, improving throughput
• Full exams 30 seconds270 exams/day
• Always-on detector-based spectral imaging avoids separate spectral scans

Negative

• Pediatric use not clinically validated for Spectral Precise Image
• 4DCT and extended field-of-view limited to treatment planning use only
• Spectral Precise Image is supplemental and does not replace clinical judgement

News Market Reaction – PHG

-1.58%

-1.58% Session close to close

In the Apr 16 session, PHG declined 1.58%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement delivers FDA 510(k) clearance for Philips’ AI-powered Verida spectral CT, highligh...

Analysis

This announcement delivers FDA 510(k) clearance for Philips’ AI-powered Verida spectral CT, highlighting throughput of 145 images/sec and up to 270 exams/day. It extends a series of AI imaging milestones, following earlier Verida launch and other AI solutions in MRI and cardiology. Investors may track adoption of detector-based spectral CT, workflow benefits from always-on spectral imaging, and how AI-enabled systems contribute to Philips’ broader medtech positioning.

Key Figures

Reconstruction speed: 145 images per second Exam appearance time: less than 30 seconds Throughput improvement: 2× faster +3 more

6 metrics

Reconstruction speed 145 images per second Verida spectral CT reconstruction rate

Exam appearance time less than 30 seconds Time for entire CT exams to automatically appear

Throughput improvement 2× faster Reconstruction speed vs previous system

Daily exam capacity up to 270 exams every day Verida Premium, 4 CIRS config, 16-hour dual shift

Adult evaluation age ≥22 years Clinical evaluation age for Spectral Precise Image

Workday duration 16 hours Dual-shift working day assumption for throughput

Previous AI Reports

5 past events · Latest: Dec 01 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 01	AI navigation rollout	Positive	+0.6%	Expanded commercial availability of LumiGuide AI 3D navigation for image-guided therapy.
Nov 30	AI CT launch	Positive	+0.6%	Launch of Verida AI-powered spectral CT with CE mark and 510(k) pending.
Nov 17	Valve repair AI assist	Positive	-2.4%	Introduction of DeviceGuide AI tracking to assist minimally invasive mitral valve repair.
Sep 17	AI MRI deployment	Positive	-0.5%	AI-enabled MRI rollout improving scan speed and capacity at Southlake Health.
Aug 27	AI ultrasound upgrade	Positive	-0.4%	Transcend Plus launch with 26 AI-enabled cardiovascular ultrasound applications.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent AI-tagged announcements (5 events) skew positive in content but have produced mixed price reactions, with 3 negative and 2 positive next-day moves, suggesting AI news has not consistently driven upside.

Recent Company History

Over the last year, Philips has repeatedly highlighted AI in imaging across CT, MRI, ultrasound, and image-guided therapy. Prior AI milestones include LumiGuide navigation, Verida’s initial launch with 510(k) pending, and multiple cardiovascular AI solutions. These events delivered modest average moves around -0.44%, indicating that while AI remains a strategic focus, related headlines have translated into only limited and sometimes negative near-term price reactions.

Key Terms

510(k), spectral ct, computed tomography, 4dct, +2 more

6 terms

510(k) regulatory

"announced it has received U.S. Food and Drug Administration 510(k) clearance for the Philips"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

spectral ct medical

"world’s first AI-powered detector-based spectral CT*, advancing diagnostic precision"

Spectral CT is an advanced form of X‑ray scanning that separates the different energy “colors” of X‑rays to tell materials apart inside the body, similar to how a prism splits light into colors so you can identify substances. For investors, it matters because it can produce clearer images, reduce contrast dose or repeat scans, and enable new diagnostic capabilities, potentially driving demand for upgraded scanners and related software in hospitals and clinics.

computed tomography medical

"Verida is a Computed Tomography X-ray system intended for diagnostic imaging in radiology"

Computed tomography (CT) is an imaging method that uses X-rays taken from multiple angles and computer processing to produce detailed cross‑sectional pictures of the body, like slicing a loaf of bread to see inside. Investors care because CT machines and their software are significant revenue drivers for medical device makers and hospitals, influence diagnostic speed and accuracy, and face regulatory, reimbursement, and technological risk that can affect company earnings.

4dct medical

"Extended field-of-view images and respiratory correlated scanning (4DCT) are for treatment"

Four-dimensional computed tomography (4DCT) is an imaging technique that captures a series of CT scans over time to show how organs and tissues move, most commonly due to breathing. For investors, 4DCT matters because it can improve the accuracy of treatment planning and the performance of devices and software used in radiation therapy and image-guided procedures—think of it as a slow-motion video that helps clinicians aim at a moving target more reliably, which can influence demand for medical equipment and related services.

radiation therapy planning medical

"oncology as part of treatment preparation and radiation therapy planning"

Radiation therapy planning is the process of designing how radiation will be delivered to a patient to destroy or shrink a tumor while minimizing harm to healthy tissue; it involves medical imaging, calculations, and a step-by-step map for treatment machines. Investors care because improvements or software used in planning can change treatment effectiveness, speed, regulatory approval, capital costs, and reimbursement, affecting demand and the value of companies that make planning tools or deliver radiation therapy services.

deep learning reconstruction technical

"AI-based deep learning reconstruction engine, designed to reduce noise and enhance image"

Deep learning reconstruction is an AI-driven technique that turns raw sensor or scan data into clearer, more detailed images by learning patterns from many examples. For investors, it matters because it can improve diagnostic accuracy, speed up procedures, reduce equipment or scanning time, and lower operational costs—similar to using a smart photo app that cleans up a blurry picture, making the underlying product or service more competitive and potentially more profitable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

04/16/2026 - 09:00 AM

April 16, 2026

Combining always-on spectral imaging with AI reconstruction to deliver enhanced levels of image quality, efficiency, and clinical insight across radiology, cardiology, and oncology

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral CT Verida system, bringing its next-generation, AI-powered spectral CT innovation to the United States.

AI-based reconstruction integrated into the imaging chain

Verida incorporates Spectral Precise Image, with a third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction, along with an AI-based deep learning reconstruction engine, designed to reduce noise and enhance image quality across CT applications [1]. Clinicians are able to customize optimal image de-noising according to their preferences.

“With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets,” said Dan Xu, Business Leader of CT at Philips. “By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways.”

Always-on detector-based spectral CT for clinical versatility

Built on Philips’ industry-leading detector-based spectral CT technology, Verida enables always-on spectral imaging without requiring separate scans or workflow changes. It includes system and software enhancements designed to support clinical workflow, including improvements to the spectral result generation pipeline and updated computing infrastructure to support performance and usability. Verida reconstructs 145 images per second, so entire exams automatically appear in less than 30 seconds – 2× faster than previously, enabling up to 270 exams every day [2].

By capturing both high- and low-energy data in a single acquisition, clinicians can access conventional and spectral results simultaneously, supporting enhanced tissue characterization and material differentiation. This approach eliminates the need for pre-selection or repeat scans, enabling first-time-right imaging and deeper clinical insight across a broad range of applications [3].

Verida is a Computed Tomography X-ray system intended for diagnostic imaging in radiology, interventional radiology, and cardiology, and in oncology as part of treatment preparation and radiation therapy planning. It is indicated for head, whole body, cardiac, and vascular CT applications in patients of all ages [1]. The system is also intended to be used for low dose CT lung cancer screening when performed within established screening protocols [4]. Extended field-of-view images and respiratory correlated scanning (4DCT) are for treatment preparation and radiation therapy planning/simulation use only [3].

For more information about the Philips Spectral CT Verida system, visit the Philips website.

*Data on file
[1] Spectral Precise Image is an AI-based reconstruction feature with supplemental data for clinical interpretation and does not replace professional clinical judgement. SPI has been clinically evaluated in adults (≥22 years); pediatric use has not been clinically validated.
[2] Spectral CT Verida Premium up to 270 (4 CIRS config) exams a day (16 hours dual shift working day) meeting the needs of radiology departments with extended work hours and very high patient throughput.
[3] See Instructions for Use for complete indications, limitations, and feature-specific restrictions.
[4] Please refer to clinical literature, including the results of the National Lung Screening Trial (N
Engl. J Med 2011; 365:395-409) and subsequent literature, for further information.

For further information, please contact:
Jayme Maniatis 
Philips Global External Relations  
Tel.: +1 617 804 8368
E-mail: Jayme.maniatis@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. 

Attachments

• Philips Verida detector-based spectral CT - 01
• Philips Verida detector-based spectral CT - 02
• Philips Verida detector-based spectral CT - 03

FAQ

What did Philips (PHG) announce on April 16, 2026 about Verida and FDA clearance?

Philips announced FDA 510(k) clearance for the Spectral CT Verida on April 16, 2026. According to the company, Verida pairs always-on detector-based spectral imaging with an AI deep-learning reconstruction engine to improve image quality, speed, and clinical workflow.

How fast does the Philips Spectral CT Verida reconstruct images and how many exams per day can PHG claim?

Verida reconstructs 145 images per second and produces full exams in under 30 seconds. According to Philips, that throughput supports up to 270 exams per day in a high-utilization, dual-shift configuration.

What clinical applications and patient populations is the PHG Verida system indicated for?

Verida is intended for radiology, interventional radiology, cardiology, and oncology diagnostics and planning. According to Philips, indications cover head, whole body, cardiac, vascular CT, and low-dose lung cancer screening within established protocols.

What are the key limitations of Spectral Precise Image in the Philips Verida system?

Spectral Precise Image is an AI-based supplemental reconstruction and does not replace clinical judgement. According to Philips, it has been clinically evaluated in adults (≥22 years) and pediatric use has not been validated.

Will Verida require changes to existing CT workflow for spectral imaging at hospitals buying PHG systems?

No major workflow change is required for spectral output because Verida provides always-on detector-based spectral imaging in a single acquisition. According to Philips, clinicians receive conventional and spectral results simultaneously without separate spectral scans.